Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 19/20 | 0.58 |
| ▸ | S1PR1 | P21453 | 10/20 | 0.48 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.48 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3817006 | 0.86 | VNN1 (0.45) | S1PR3AR | |
| SCHEMBL18957967 | 0.83 | HDAC6 (0.44) | S1PR3 | |
| SCHEMBL22099996 | 0.82 | S1PR3 (0.54) | S1PR3S1PR1S1PR4S1PR2AR | |
| SCHEMBL15955802 | 0.82 | S1PR3 (0.54) | S1PR3S1PR1S1PR4S1PR2AR | |
| SCHEMBL20633537 | 0.81 | PLAU (0.45) | S1PR3AR | |
| SCHEMBL20787390 | 0.81 | S1PR3 (0.59) | S1PR3S1PR1S1PR4S1PR2AR | |
| SCHEMBL12670890 | 0.81 | S1PR3 (0.57) | S1PR3S1PR1S1PR4S1PR2 | |
| SCHEMBL20787536 | 0.81 | HDAC8 (0.47) | S1PR3S1PR1AR | |
| SCHEMBL996704 | 0.80 | MRGPRX4 (0.56) | S1PR3 | |
| SCHEMBL2369495 | 0.80 | S1PR3 (0.51) | S1PR3S1PR1S1PR4S1PR2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230406851-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2023-12-21 | — | — | US | disclosed |
| EP-3998267-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | Bellus Health Cough Inc. (CA) | 2022-05-18 | — | — | EP | disclosed |
| US-20220062290-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2022-03-03 | — | — | US | disclosed |
| US-20220062290-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2022-03-03 | — | — | US | disclosed |
| EP-3381917-B1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | BELLUS HEALTH COUGH INC (CA) | 2021-09-08 | — | — | EP | disclosed |
| US-20210228588-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2021-07-29 | — | — | US | disclosed |
| US-20210228588-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2021-07-29 | — | — | US | disclosed |
| US-20200390779-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2020-12-17 | — | — | US | disclosed |
| US-20200390779-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2020-12-17 | — | — | US | disclosed |
| US-20200138826-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2020-05-07 | — | — | US | disclosed |
| US-9814725-B2 | Imidazopyridine compounds and uses thereof | NEOMED INSTITUTE (CA) | 2017-11-14 | — | — | US | disclosed |
| US-20170143730-A1 | Imidazopyridine Compounds and Uses Thereof | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2017-05-25 | — | — | US | disclosed |
| US-20170143730-A1 | Imidazopyridine Compounds and Uses Thereof | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2017-05-25 | — | — | US | disclosed |
| US-9598409-B2 | Imidazopyridine compounds and uses thereof | NEOMED INSTITUTE (CA) | 2017-03-21 | — | — | US | disclosed |
| US-9598409-B2 | Imidazopyridine compounds and uses thereof | NEOMED INSTITUTE (CA) | 2017-03-21 | — | — | US | disclosed |
| US-20150361078-A1 | Imidazopyridine Compounds and Uses Thereof | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2015-12-17 | — | — | US | disclosed |
| US-20150361078-A1 | Imidazopyridine Compounds and Uses Thereof | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2015-12-17 | — | — | US | disclosed |
| EP-2951177-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | Neomed Institute (CA) | 2015-12-09 | — | — | EP | disclosed |
| WO-2014117274-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | NEOMED INSTITUTE (CA) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014117274-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | NEOMED INSTITUTE (CA) | 2014-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406851-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | NISCH, ABL1, PAICS | S1PR3 1929/4885S1PR1 2439/4885S1PR4 1517/4885 |
| US-20200390779-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | NISCH, ABL1, PAICS | S1PR3 1929/4885S1PR1 2439/4885S1PR4 1517/4885 |
| US-20150361078-A1 | Imidazopyridine Compounds and Uses Thereof | NISCH, ABL1, PAICS | S1PR3 1929/4885S1PR1 2439/4885S1PR4 1517/4885 |
| US-20220062290-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | NISCH, ABL1, PAICS | S1PR3 1929/4885S1PR1 2439/4885S1PR4 1517/4885 |
| US-20200138826-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | NISCH, ABL1, PAICS | S1PR3 1929/4885S1PR1 2439/4885S1PR4 1517/4885 |
| US-20170143730-A1 | Imidazopyridine Compounds and Uses Thereof | NISCH, ABL1, PAICS | S1PR3 1929/4885S1PR1 2439/4885S1PR4 1517/4885 |
| US-20210228588-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | NISCH, ABL1, PAICS | S1PR3 1929/4885S1PR1 2439/4885S1PR4 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.